Innovations in asthma therapy: is there a role for inhaled statins?

Zeki, Amir A.; Elbadawi-Sidhu, Mona

doi:10.1080/17476348.2018.1457437

Cited by 23 publications

(19 citation statements)

References 126 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In terms of the alleviating effects of statins on asthma symptoms and asthmatic decrease of pulmonary function, our results do not support the assumption that inhaled statins might have more advantage over those ingested or injected (10), since these effects might involve a direct central drug action that is independent of the deposition of inhaled drugs in the lungs.…”

Section: Discussioncontrasting

confidence: 91%

“…However, some small randomized clinical trials using oral statins have yielded contradictory results. While a consistent anti-inflammatory effect of statins is validated, improved clinical outcomes in terms of symptoms or pulmonary function are not demonstrated [for review, see (10)]. The results from this study suggest that in OVA-sensitized rats, the rosuvastatin-induced improvement of pulmonary function is closely related to the reversed increase of airway vagal activity.…”

Section: Discussionmentioning

confidence: 72%

“…Both preclinical studies in animal models and some randomized clinical trials have implicated that statins also act as modulators of immune cells and are able to alleviate asthma and chronic obstructive pulmonary diseases (COPD) [for review, see (9)(10)(11)(12)(13)]. In particular, inhaled statins are thought to be more prospective in asthma treatment due to the assumed heavier drug deposition in the lungs (10). A latest retrospective clinical study even shows that in-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19 (14).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Rosuvastatin blocks allergic airway vagal hypertonia via reversed central CD73 downregulation in rats

Chen

Zeng

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background In asthma, the decrease of pulmonary function and occurrence of pulmonary inflammation are largely attributed to the increase of airway vagal activity, of which the genesis involves disrupted degradation of central extracellular ATP to adenosine due to decreased expression and activity of ecto-5'-nucleotidase (CD73). Meanwhile, the therapeutic use of statins reportedly is able to alleviate asthma; however, the mechanisms remain unclear. This study test whether rosuvastatin is able to attenuate the downregulation of central CD73 and, subsequently, attenuate the increase of airway vagal activity in the rat model of allergic asthma. Methods An experimental rat model of allergic asthma was prepared using ovalbumin. During the sensitization period, ovalbumin was inhaled alone or in combination with rosuvastatin. Plethysmographic measurement of pulmonary function was used to evaluate airway vagal activity; molecular biological assay was used to examine the expression and activity of medullary CD73 and the expression of eosinophil cationic protein 1 (ECP1) in the lungs. Results In ovalbuminsensitized rats, the decreases in the expression and activity of medullary CD73 and the increases in the expression of ECP1 in the lungs and ATP concentration in cerebral spinal fluid were completely reversed by inhaled rosuvastatin, so was the increase of airway vagal activity manifested by the atropine-sensitive increase of airway resistance and decrease of airway compliance. Conclusions In the rat model of allergic asthma, inhaled rosuvastatin reverses the decreases in the expression and activity of brainstem CD73, which prevents pulmonary function decrease via an abolished increase of airway vagal activity.

show abstract

Section: Discussioncontrasting

confidence: 91%

Section: Discussionmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rosuvastatin blocks allergic airway vagal hypertonia via reversed central CD73 downregulation in rats

Chen

Zeng

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“… 82 – 84 RCTs in severe asthma are lacking and studies using statins delivered by inhalation are also warranted. 84 Evidence of clinical benefit of metformin in asthma is also growing, 85 – 87 although it has seldom been investigated in real-life clinical settings. In particular, a decrease in asthma exacerbations in response to metformin has been reported in different populations.…”

Section: Literature Review and Discussionmentioning

confidence: 99%

“…Epidemiological and observational studies pointed towards therapeutic benefits in asthma, but RCTs using oral statins yielded conflicting results. [82][83][84] RCTs in severe asthma are lacking and studies using statins delivered by inhalation are also warranted. 84 Evidence of clinical benefit of metformin in asthma is also growing, [85][86][87] although it has seldom been investigated in real-life clinical settings.…”

Section: Current Therapeutic Interventions: Where Do We Stand?mentioning

confidence: 99%

<p>Metabolic Dysfunction and Asthma: Current Perspectives</p>

Pité¹,

Aguiar²,

Morello³

et al. 2020

JAA

View full text Add to dashboard Cite

The increasing knowledge of the mechanisms involved in metabolism is shifting the paradigms by which the pathophysiology of many pulmonary diseases is understood. Metabolic dysfunction is recognized in obesity-associated asthma, but other metabolic conditions have been shown to be independently related to asthma. Novel insights have also recently been brought by metabolomics in this filed. The purpose of this review is to discuss current perspectives regarding metabolic dysfunction in asthma, from obesity-related asthma to other metabolic conditions and the role of current pharmacological therapeutic strategies and lifestyle interventions. Obesity is a well-recognized risk factor for asthma across the lifespan, which is generally associated with poorer response to current available treatments, rendering a more severe, refractory disease status. Besides the epidemiological and clinical link, untargeted metabolomics studies have recently supported the obesity-associated asthma phenotype at the molecular level. Not only obesity-related, but also other aspects of metabolic dysregulation can be independently linked to asthma. These include hyperinsulinemia, dyslipidemia and hypertension, which need to be taken into account, even in the non-obese patient. Untargeted metabolomics studies have further highlighted several other metabolic pathways that can be altered in asthma, namely regarding oxidative stress and systemic inflammation, and also suggesting the importance of microbiota in asthma pathogenesis. Considering the reduced response to corticosteroids, other pharmacologic treatments have been shown to be effective regardless of body mass index. Non-pharmacologic treatments (namely weight reduction and dietary changes) may bring substantial benefit to the asthmatic patient. Taken together, this evidence points towards the need to improve our knowledge in this filed and, in particular, to address the influence of environmental factors in metabolic dysfunction and asthma development. Personalized medicine is definitely needed to optimize treatment, including a holistic view of the asthmatic patient in order to set accurate pharmacologic therapy together with dietary, physical exercise and lifestyle interventions.

show abstract

The Potential Protective Effects of Statins in Chronic Rhinosinusitis: A Case–Control Study

Gilani

Bhattacharyya

2020

The Laryngoscope

View full text Add to dashboard Cite

Objectives/Hypothesis To determine the potential protective effect of prior statin use on the subsequent diagnosis of chronic rhinosinusitis (CRS). Study Design Retrospective, case‐control. Methods Electronic medical records for all patients seen in the otolaryngology clinic in 2019 and receiving a diagnosis of CRS were reviewed for the presence or absence of active prior statin use within 365 days of the visit. Similarly, prior statin use in a control group of patients without any diagnosis of CRS was also determined. Statin exposure in CRS patients was compared to statin exposure in control patients with 1:2 matching on age and sex with chi‐square and odds ratios were computed. Results In 2019, 3655 patients (mean age, 52.9 years, 56.4% female) were identified with a diagnosis of chronic rhinosinusitis versus 41,636 patients without any diagnosis of CRS. All chronic rhinosinusitis patients were successfully matched to 7310 controls. 6.3% of CRS patients (229 patients) had prior statin use, versus 8.5% (624 patients) of control patients. The average mean duration of statin use prior to visit was not significantly different between CRS and control patients (mean days, 202.3 days versus 205.6 days, respectively; P = .697). The presence of a statin medication in use was associated with a significant protective effect against a subsequent diagnosis of CRS with and odds ratio for CRS diagnosis of 0.716 (95% confidence interval, 0.612–0.838) in those patients taking a statin medication (P < .001). Conclusions The use of a statin medication was associated with a significant reduction in subsequent diagnosis of chronic rhinosinusitis. Level of Evidence 3 Laryngoscope, 131:E1431–E1433, 2021

show abstract

Innovations in asthma therapy: is there a role for inhaled statins?

Cited by 23 publications

References 126 publications

Rosuvastatin blocks allergic airway vagal hypertonia via reversed central CD73 downregulation in rats

Rosuvastatin blocks allergic airway vagal hypertonia via reversed central CD73 downregulation in rats

<p>Metabolic Dysfunction and Asthma: Current Perspectives</p>

The Potential Protective Effects of Statins in Chronic Rhinosinusitis: A Case–Control Study

Contact Info

Product

Resources

About